News
INO
1.760
+2.92%
0.050
Inovio Pharmaceuticals (INO) Stock Offers No Clear Value Read After 110% Jump
Simply Wall St · 1d ago
Inovio Pharmaceuticals Prepares First Product Launch After VOCERYQ FDA Approval
NASDAQ · 3d ago
INOVIO: EMA Filing for VOCERYQ Supports European Expansion; Analyst Maintains $5 Price Target
TipRanks · 4d ago
INOVIO Seeks European Approval For VOCERYQ In Rare HPV-Related Disease
NASDAQ · 4d ago
Inovio submits CMA application to EMA for voceryq
TipRanks · 4d ago
INOVIO Submits Conditional Marketing Authorization Application To EMA For VOCERYQ In Adults with Recurrent Respiratory Papillomatosis
Benzinga · 4d ago
INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ™ in Adults with Recurrent Respiratory Papillomatosis
PR Newswire · 4d ago
Inovio Pharmaceuticals, Inc. Appoints Jeffrey Libson to Board of Directors
NASDAQ · 4d ago
Inovio Pharmaceuticals Inc. Stock Rises 16.4%, Outperforms Peers
Dow Jones · 4d ago
Largest borrow rate increases among liquid names
TipRanks · 5d ago
Weekly Report: what happened at INO last week (1109-1113)?
Weekly Report · 6d ago
Inovio Pharma Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 11/12 12:01
INOVIO’s VOCERYQ Outlook Supports Reiterated Buy Rating and Unchanged $5 Price Target
TipRanks · 11/12 11:55
HC Wainwright & Co. Reiterates Buy on Inovio Pharmaceuticals, Maintains $5 Price Target
Benzinga · 11/12 11:50
Inovio Earnings Call: VOCERYQ Launch Sets 2027 Path
TipRanks · 11/12 00:05
Inovio Pharma Price Target Cut to $6.00/Share From $8.00 by Piper Sandler
Dow Jones · 11/11 14:39
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $6
Benzinga · 11/11 14:29
Inovio price target lowered to $6 from $8 at Piper Sandler
TipRanks · 11/11 13:56
INOVIO to Participate in Upcoming Investor Conferences
PR Newswire · 11/11 13:05
FDA Drug Approvals In October 2026
NASDAQ · 11/11 07:10
More
Webull provides a variety of real-time INO stock news. You can receive the latest news about Inovio Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.